Danaher (DHR) Q4 Earnings Beat, Biotechnology Sales Dip Y/Y

Danaher Corporation’s (DHR) fourth-quarter 2023 adjusted earnings (excluding 59 cents from non-recurring items) of $2.09 per share surpassed the Zacks Consensus Estimate of$1.90. The bottom line declined 17.7% year over year.Danaher’s net sales of $6,405 million outperformed the consensus estimate of$5,990 million. However, the metric declined 10.2% year over year due to a decrease in sales of COVID-related products and weakness in the Biotechnology and Diagnostics segments.Organic sales in the quarter de ...